glp-1 heart failure medications are not just for weight loss — they are the most important drug class of our lifetime. 🫀 A 2025 meta-analysis of 99,599 patients confirmed: ✓ 20% reduction in major Emerging Heart Failure Therapies in

What Each Compound Does in the GLOW Blend BPC-157 is a 15-amino-acid peptide first isolated from gastric juice

Tackling R&D, food tech company Nuritas is partnering with brands to put novel peptides in supps, skincare, and snacks

The GLP-1 Wave Is Just Getting Started The global GLP-1 receptor market was valued at $53.46B in 2024 and is projected to reach $156.71B by 2030

however, they are highly applicable to disease diagnosis and can deliver large doses of drug solutions

Our experience suggests that while a systemic dose will eventually reach the ankle, a localized dose may create a much higher concentration gradient in the target tissue for a more potent and immediate effect

Kerksick, C., & Willoughby, D